Abstract
Importance Tobacco use is heavily influenced by environmental factors with significant genetic contributions. An extensive evaluation of the genetic variants predisposing to tobacco use is necessary to understand associated health risks and formulate equitable health policies.
Objective To evaluate the predictive performance, risk stratification, and potential systemic health effects of tobacco use disorder (TUD) predisposing germline variants using a European-derived polygenic score (PGS) in the UCLA ATLAS biobank.
Design, Setting, and Participants Publicly available TUD-PGS, developed in European ancestry individuals, was evaluated in participants enrolled in the UCLA ATLAS biobank - a multi-ancestry, hospital-based biobank with participant genotypes linked to their de-identified medical records.
Main Outcomes and Measures The outcomes of interest were (a) tobacco use disorder and (b) 1,847 phenotypes, identified by phecodes (aggregated ICD codes) extracted from electronic health records.
Results Among genetically inferred ancestry groups (GIAs), TUD-PGS associated with TUD in European American (EA) (OR: 1.20, CI: [1.16, 1.24]), Hispanic/Latin American (HL) (OR:1.19, CI: [1.11, 1.28]), and East Asian American (EAA) (OR: 1.18, CI: [1.06, 1.31]) GIAs but not in African American (AA) GIA (OR: 1.04, CI: [0.93, 1.17]). Similarly, TUD-PGS offered strong risk stratification across quantiles in the EA and HL GIAs but inconsistently in EAA and AA GIAs. In a cross-ancestry phenome-wide association meta-analysis, TUD-PGS was associated with cardiac, respiratory, psychiatric, and metabolic phecodes (17 phecodes at P < 2.57e-5). In individuals with no history of smoking (never-smokers), the top TUD-PGS associations were obesity and alcohol-related disorders (P = 3.54E-07, 1.61E-06). Mendelian Randomization (MR) analysis provides evidence of a causal association between tobacco use and adiposity measures.
Conclusions and Relevance This study provides an investigation of TUD-PGS across multiple ancestries and a range of phenotypes in a hospital-based biobank, suggesting shared biological pathways between tobacco use, alcohol use disorder, and obesity. European ancestry TUD-PGS demonstrated inconsistent performance in non-European ancestries for risk prediction and stratification. Equitable clinical translation of TUD-PGS will require the inclusion of multiple ancestry populations at all levels of TUD genetic research. Additionally, TUD-predisposed individuals may require comprehensive tobacco use management approaches to address underlying addictive tendencies.
Question How does a European-derived polygenic score (PGS) for tobacco use disorder (TUD) perform in ancestrally diverse individuals within a real-world medical system and what are the systemic health risks in TUD predisposed individuals?
Findings European ancestry TUD-PGS performs inconsistently in non-European ancestry populations. TUD-PGS correlates with cardiometabolic, respiratory, and psychiatric phenotypes. In individuals with no history of smoking, TUD-PGS correlates with obesity and alcohol-related disorders.
Meaning Existing TUD-PGS is not generalizable across ancestries. TUD-predisposed individuals are at risk for obesity and alcohol use disorder in the absence of smoking behavior, suggesting shared genetic etiology between these phenotypes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
VV is funded by NIH/NIDCR 5K12DE027830-04. RJ is funded by NSF DGE-1829071. The ATLAS Community Health Initiative is supported by UCLA Health, the David Geffen School of Medicine, and a grant from the UCLA Clinical and Translational Science Institute (UL1TR001881). BP was partially supported by NIH awards R01 HG009120, R01 MH115676, R01 CA251555, R01 AI153827, R01 HG006399, R01 CA244670, and U01 HG011715.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Patient Recruitment and Sample Collection for Precision Health Activities at UCLA is an approved study by the UCLA Institutional Review Board (UCLA IRB). IRB#17-001013.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Author information:
Vidhya Venkateswaran: vvenkat{at}ucla.edu, 10833 Le Conte Ave, CHS 33-365, Los Angeles, CA 90024, Phone: 310-825-3291, Fax: 310-825-4846
Kristin Boulier: kboulier{at}mednet.ucla.edu
Yi Ding: yiding920{at}g.ucla.edu
Ruth Johnson: ruthjohnson{at}ucla.edu
Arjun Bhattacharya: abtbhatt{at}g.ucla.edu
Bogdan Pasaniuc: pasaniuc{at}g.ucla.edu
Updated to include acknowledgments in the main text.
Data Availability
All data produced in the present work are contained in the manuscript.
